





IDFC MULTI CAP FUND

(Previously known as IDFC Premier Equity Fund w.e.f. May 02, 2018)

Multi Cap Fund - An open ended equity scheme investing across large cap, mid cap, small cap stocks.

FUND PHILOSOPHY

This is a multi-cap fund with equal weights in large, mid and small caps currently. The fund focuses on a benchmark agnostic investing style with a distinct underweight on financials and overweight on consumption and domestic cyclical in the current market conditions. At a stock level, the fund focuses on companies which are operating in segments where penetration of organized is still increasing and conversion to brands will be a key driver for long term growth. The fund favours companies which generate positive operating cash flow and consistently improve their Return on Capital Employed (RoCE). From time to time, the fund identifies stocks which are strong transformational targets both from operating parameters as well as corporate governance. The fund also aims to identify and capitalize on long term themes which could generate superior returns, even if they are present in the small cap segment.

OUTLOOK

Indian equities continued their upward momentum in July with markets rebounding by 46% from March lows despite the relentless increase in daily new Covid cases and sharp earnings downgrades.

Going forward, the pace of economic recovery would depend largely on the extent of local lockdowns on account of spread of Covid-19. Markets seems to have run ahead of fundamentals and are less than 10% lower than all-time highs. Global and domestic liquidity seems to have played a significant part in the sharp upmove seen in the markets. Investors should tread with caution as the number of cases and deaths in India continue to rise. Also, earnings uncertainty for FY21 is fairly high with a wide range of analyst estimates. Various valuation parameters after dropping to an "attractive" zone in April'20 have moved into the "expensive" zone. Investors need to be cautious at current levels given the combination of higher valuation and a possibility of a slower than expected earnings recovery in FY21.

Face Value per Unit (in ₹) is 10

Dividend is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of dividend, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

FUND FEATURES: (Data as on 31st

July'20)

Category: Multicap

Monthly Avg AUM: ₹4,680.96 Crores Inception Date: 28th September

2005

Fund Manager: Mr. Anoop Bhaskar (w.e.f.

30/04/2016)

Benchmark: S&P BSE 500 TRI

Minimum Investment Amount: ₹10,000/and any amount thereafter. (Units of IDFC Multi Cap Fund, shall be available for lump sum subscription w.e.f. May 07, 2018)

Exit Load:

- If redeemed/switched out within 365 days from the date of allotment:
 - ▶ Upto 10% of investment:Nil,
 - ▶ For remaining investment: 1% of applicable NAV.
- If redeemed / switched out after 365 days from date of allotment: Nil. (w.e.f. May 08, 2020)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)

Minimum SIP Investment Amount:

₹100/- (Minimum 6 instalments) (w.e.f. 2nd May 2018)

Options Available: Growth, Dividend -(Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

Other Parameters:

Beta: 0.90 **R Square:** 0.92

Standard Deviation (Annualized):


20.48%

PLAN	DIVIDEND RECORD DATE	₹/UNIT	NAV
REGULAR	20-Mar-20	1.39	25.5900
	01-Mar-19	1.67	32.2300
	22-Mar-18	2.17	35.0577
DIRECT	20-Mar-20	1.46	26.8600
	01-Mar-19	1.74	33.5900
	22-Mar-18	2.25	36.2848



Name of the Instrument Ratings %		Name of the Instrument Ratings 9	
Equity and Equity related Instruments	98.18%	Sun Pharmaceutical Industries	1.96%
Banks	16.98%	Lupin	1.37%
CICI Bank	4.58%	Divi's Laboratories	0.87%
HDFC Bank	4.30%	Cadila Healthcare	0.79%
Axis Bank	2.70%	Auto Ancillaries	4.92%
Kotak Mahindra Bank	2.49%	Minda Industries	1.30%
City Union Bank	1.75%	MRF	1.16%
CICI Bank - Equity Futures	0.75%	Amara Raja Batteries	1.12%
State Bank of India - Equity Futures	0.42%	Wheels India	0.75%
Consumer Non Durables	14.95%	Bosch	0.59%
Britannia Industries	2.94%	Commercial Services	3.85%
Hindustan Unilever	2.82%	3M India	3.85%
TC	2.23%	Telecom - Services	3.02%
Nestle India	1.93%	Bharti Airtel	3.02%
Procter & Gamble Hygiene and Health Ca	re 1.79%	IT Consulting & Other Services	2.70%
Asian Paints	1.53%	Cognizant Technology Solutions	
Jubilant Foodworks	1.05%	Corp - International Equities	2.70%
S H Kelkar and Company	0.43%	Cement	2.56%
United Spirits	0.23%	UltraTech Cement	2.56%
Consumer Durables	9.84%	Retailing	1.76%
/oltas	3.00%	Avenue Supermarts	1.20%
Bata India	2.67%	Future Retail	0.44%
Crompton Greaves Consumer Electricals	2.41%	Future Lifestyle Fashions	0.12%
Titan Company	1.10%	Construction Project	1.50%
Greenlam Industries	0.66%	Larsen & Toubro	1.12%
Finance	9.63%	Power Mech Projects	0.37%
Multi Commodity Exchange of India	2.84%	Auto	1.45%
HDFC Life Insurance Company	1.86%	Mahindra & Mahindra	1.36%
CICI Securities	1.66%	Mahindra & Mahindra - Equity Futures	0.09%
CICI Lombard General Insurance Compa	ny 1.52%	Ferrous Metals	1.28%
JM Financial	1.05%	APL Apollo Tubes	1.28%
Mas Financial Services	0.70%	Pesticides	0.96%
Chemicals	5.18%	Dhanuka Agritech	0.96%
Atul	2.62%	Textiles - Cotton	0.86%
ine Organic Industries	1.39%	Vardhman Textiles	0.86%
Pidilite Industries	1.17%	Transportation	0.69%
ndustrial Products	5.16%	Transport Corporation of India	0.69%
Supreme Industries	1.54%	Industrial Capital Goods	0.44%
Schaeffler India	1.42%	ABB India	0.44%
AIA Engineering	1.28%	Media & Entertainment	0.27%
Kirloskar Pneumatic Company	0.49%	Entertainment Network (India)	0.27%
Disa India	0.43%	Construction	0.15%
Software	5.04%	Poddar Housing and Development	0.15%
nfosys	5.04%	Net Cash and Cash Equivalent	1.82%
Pharmaceuticals	4.99%	Grand Total	100.00







This product is suitable for investors who are seeking*:

- To create wealth over long term
- Investment predominantly in equity and equity related instruments across market capitalisation.

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.











